Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update
Claudio Borghi, Justyna Domienik‐Karłowicz, Andrzej Tykarski, Krzysztof J. Filipiak, Miłosz Jaguszewski, Krzysztof Narkiewicz, Marcin Barylski, Artur Mamcarz, Jacek Wolf, Giuseppe Mancia
Abstract
This document updates previous documents and provides a condensed overview of the existing information. It aims to support healthcare professionals in developing optimal approaches to managing patients struggling with hyperuricemia (HU) and its related health conditions. The intention is to enhance the decision-making process for healthcare professionals in their daily clinical activities. However, it is important to note that the responsible healthcare provider should make the final decisions regarding patient care, considering what is most appropriate in the given context. Particular attention will be given to the latest advancements in this field. First, the focus herein,was on: — pointing to the need to standardize the definition of HU; — paying attention to HU in patients with chronic kidney disease (CKD); — paying attention to HU values associated with the risk of various ardiovascular diseases (CVD); — focusing on new medications supporting HU treatment with allopurinol in patients at increased cardiovascular risk.